NDA for angiotensin II receptor blocker in Japan shows Takeda’s dual-market strategy
This article was originally published in Scrip
Executive Summary
Takeda Pharmaceutical has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for its investigational compound TAK-536 (azilsartan) for the treatment of hypertension. Azilsartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone.